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*Corresponding Author. E-mail: sandra.peake@sa.gov.au.Study objective: The influence of the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
on the conduct of future sepsis research is unknown. We seek to examine the potential effect of the new definitions on
the identification and outcomes of patients enrolled in a sepsis trial.
Methods: This was a post hoc analysis of the AustralasianResuscitation in Sepsis Evaluation (ARISE) trial of early goal-directed
therapy that recruited 1,591 adult patients presenting to the emergency department (ED) with early septic shock diagnosed
by greater than or equal to 2 systemic inflammatory response syndrome criteria and either refractory hypotension or
hyperlactatemia. The proportion of participants who would have met the Sepsis-3 criteria for quick Sequential Organ Failure
Assessment (qSOFA) score, sepsis (an increased Sequential Organ Failure Assessment score 2 because of infection) and
septic shock before randomization, their baseline characteristics, interventions delivered, and mortality were determined.
Results: There were 1,139 participants who had a qSOFA score of greater than or equal to 2 at baseline (71.6% [95%
confidence interval {CI} 69.4% to 73.8%]). In contrast, 1,347 participants (84.7% [95% CI 82.9% to 86.4%]) met the
Sepsis-3 criteria for sepsis. Only 1,010 participants were both qSOFA positive and met the Sepsis-3 criteria for sepsis
(63.5% [95% CI 61.1% to 65.8%]). The Sepsis-3 definition for septic shock was met at baseline by 203 participants
(12.8% [95% CI 11.2% to 14.5%]), of whom 175 (86.2% [95% CI 81.5% to 91.0%]) were also qSOFA positive. Ninety-day
mortality for participants fulfilling the Sepsis-3 criteria for sepsis and septic shock was 20.4% (95% CI 18.2% to 22.5%)
(274/1,344) and 29.6% (95% CI 23.3% to 35.8% [60/203]) versus 9.4% (95% CI 5.8% to 13.1%) (23/244) and 17.1%
(95% CI 15.1% to 19.1% [237/1,388]), respectively, for participants not meeting the criteria (risk differences 11.0%
[95% CI 6.2% to 14.8%] and 12.5% [95% CI 6.3% to 19.4%], respectively).
Conclusion: Most ARISE participants did not meet the Sepsis-3 definition for septic shock at baseline. However, the
majority fulfilled the new sepsis definition andmortality was higher than for participants not fulfilling the criteria. A quarter
of participants meeting the new sepsis definition did not fulfill the qSOFA screening criteria, potentially limiting its utility as
a screening tool for sepsis trials with patients with suspected infection in the ED. The implications of the new definitions
for patients not eligible for recruitment into the ARISE trial are unknown. [Ann Emerg Med. 2017;70:553-561.]
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Background
An international task force of experts in sepsis
pathophysiology recently generated a new set of definitions
for sepsis and septic shock (Third International Consensus
Definitions for Sepsis and Septic Shock [Sepsis-3]).1 The
impetus for revising the definitions was awareness that
elements of the 1991 and 2001 consensus conferencehe Australasian and Resuscitation in Sepsis Evaluation
their affiliations are listed in the Appendix.
4 : October 2017definitions,2,3 which incorporated the requirement for 2 or
more systemic inflammatory response syndrome (SIRS)
criteria, were outdated and did not accurately identify
patients with presumed sepsis and septic shock. Data from
Australia and New Zealand suggested that 1 in 8 patients
admitted to the ICU with infection and new organ failure
did not fulfill the SIRS criteria for defining sepsis, despite
having substantial mortality.4
The new Sepsis-3 definitions use the Sequential Organ
Failure Assessment (SOFA)5 score to identify sepsis andAnnals of Emergency Medicine 553
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What is already known on this topic
International consensus sepsis definitions have
recently changed (Third International Consensus
Definitions for Sepsis and Septic Shock [Sepsis-3]).
The effect of this change on identification and
outcomes of patients compared with that of previous
sepsis definitions (Sepsis-2) is unknown.
What question this study addressed
How do categories of patients classified by both
Sepsis-2 and -3 criteria compare both in terms of
definitional overlap and outcomes?
What this study adds to our knowledge
Most patients who met the Sepsis-2 definitions of
severe sepsis or septic shock did not meet the Sepsis-3
criteria for septic shock. A quarter of patients meeting
Sepsis-3 criteria did not fulfill quick Sequential
Organ Failure Assessment (qSOFA) criteria.
How this is relevant to clinical practice
qSOFA appears to have limited utility as a sepsis
screening tool in the emergency department. Sepsis-3
may miss patients considered to have sepsis by Sepsis-
2 definitions.septic shock. Moreover, they provide a screening tool, the
quick Sequential Organ Failure Assessment (qSOFA) score,
to assist in the rapid identification of patients with
suspected infection who are at higher risk of mortality.
Lacking a criterion standard test for diagnosing sepsis, the
qSOFA screening tool and the revised definitions for sepsis
and septic shock were based on a systematic literature
review, a Delphi study, and retrospective analyses of the
Surviving Sepsis Campaign database and 5 electronic health
record databases for adult patients with suspected infection
in 167 US hospitals and 1 German hospital.6 The
underlying goal was to develop definitions that would lead
to more timely identification and resuscitation of patients
with sepsis, in particular those with poor outcomes, more
reliable epidemiologic data, and less heterogeneity in
populations included in clinical sepsis trials.
Importance
The potential research implications of adopting the
proposed new definitions for the screening, identification,
and inclusion of patients in sepsis trials have not yet been
evaluated, in particular for trials involving prompt554 Annals of Emergency Medicinerecognition and early resuscitation. It is not known how the
populations of patients included in recent sepsis trials using
previous definitions might differ from those likely to be
included in future equivalent trials using the new definitions.
The effect on key trial design features such as feasibility,
sample size calculations, and recruitment is also unknown.
Moreover, it is uncertain how informative comparisons of
results across trials might be influenced by the variability in
selection of patients if different definitions are used.
Goals of This Investigation
We sought to explore the utility and potential effects of
the new Sepsis-3 definitions for qSOFA, sepsis, and septic
shock on the screening, identification, recruitment, and
outcomes of participants, using data from patients
previously enrolled in a large, multicenter, randomized,
clinical trial conducted in patients presenting to the
emergency department (ED) with early septic shock.
MATERIALS AND METHODS
Study Design and Setting
We conducted a post hoc analysis of the Australasian
Resuscitation in Sepsis Evaluation (ARISE) trial to
determine the proportion of patients enrolled with the
SIRS-based criteria that met the new Sepsis-3 definitions
for qSOFA, sepsis, and septic shock before randomization;
their baseline characteristics; interventions delivered; and
outcomes, including mortality, duration of organ support,
and ICU and hospital length of stay.7
ARISE was a large, multicenter, randomized trial of early
goal-directed therapy versus usual care in patients presenting
to the ED with early septic shock. The trial was conducted
between October 2008 and April 2014 in 51 tertiary
(academic) and nontertiary metropolitan and rural hospitals
in Australia, New Zealand, Finland, Hong Kong, and the
Republic of Ireland. ARISE was endorsed by the Australian
and New Zealand Intensive Care Society Clinical Trials
Group and Australasian College for Emergency Medicine.
The results of the primary analysis have been previously
published.7 We included data from the 1,591 trial
participants in the intention-to-treat population in this report.
Selection of Participants
The ARISE trial inclusion criteria were aged 18 years or
older, suspected or confirmed infection, 2 or more SIRS
criteria (ie, core temperature <36.0C (96.8F) or
>38.0C (100.4F), pulse rate >90 beats/min, respiratory
rate >20 breaths/min, or PaCO2 <32 mm Hg or
requirement for invasive ventilation for an acute process
and WBC count >12.0103/mL or <4.0103/mL or
>10% immature bands), and either refractory hypotensionVolume 70, no. 4 : October 2017
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arterial pressure <65 mm Hg after an intravenous fluid
challenge of 1,000 mL or more administered within a 60-
minute period) or hypoperfusion (defined as a blood lactate
level of 4 mmol/L or more).7
Key exclusion criteria related to an inability to deliver any
or all elements of the early goal-directed therapy resuscitation
algorithm within the study timeframe, imminent death, or
expected death from an underlying condition before 90 days.
Patients were eligible for enrollment if they met all the
inclusion criteria and none of the exclusion criteria within 6
hours of presenting to the ED.7
Time to meeting the final study entry criterion was a
median of 1.4 hours (95% confidence interval [CI] 0.6 to
2.5 hours) after presentation to the ED and enrollment
occurred 2.7 hours (95% CI 2.0 to 3.9 hours) after
presentation.7
Data Collection and Processing
Baseline prerandomization characteristics included
demographic data, Acute Physiology and Chronic Health
Evaluation (APACHE) score, and physiologic, laboratory,
and microbiologic variables. We also recorded receipt and
duration of organ support (vasopressors, invasive
ventilation, and renal replacement therapy), ICU and
hospital duration of stay, and mortality at ICU and hospital
discharge and at 90 days.
Outcome Measures
The proportion of patients meeting the Sepsis-3 qSOFA
criteria (score of 2 from respiratory rate 22 breaths/min,
systolic blood pressure 100 mm Hg, Glasgow Coma Scale
[GCS] score<15), the SOFA-based definitions for sepsis (an
increase of 2 in the SOFA score), and the SOFA-based
definition for septic shock (an increase of 2 in the SOFA
score, a requirement for vasopressors, and a blood lactate level
>2 mmol/L) were calculated with the worst physiologic,
laboratory, and intervention variables obtained after ED
presentation and before randomization into ARISE.7Missing
clinical and laboratory data were assumed to be normal for
the purpose of calculating the qSOFA and SOFA scores and
for determining the presence of septic shock.
Primary Data Analysis
We performed our analysis with SAS (version 9.4; SAS
Institute, Inc., Cary, NC). Categorical data are presented as
number and proportion with 95% CIs. Continuous data are
presented as mean (standard deviation) or median
(interquartile range) as appropriate. All missing values were
assumed to be normal. To account for missingness, we
conducted a sensitivity analysis using 2 approaches. First, inVolume 70, no. 4 : October 2017accordance with Seymour et al8 and Raith,9 chained-
equations multiple imputation was performed with
missingness conditional on observed baseline covariates and
assumed to be “missing at random.” A total of 11 imputed
data sets were created, with median results reported.
Furthermore, in contrast to the conventional approach of
assigningmissing values to be normal, to establish the extreme
case scenario, all missing values were assigned to be abnormal.RESULTS
Characteristics of Study Subjects
Of 1,591 participants included in the ARISE study,
1,139 (71.6% [69.4% to 73.8%]) met 2 or more qSOFA
bedside screening criteria before randomization (qSOFA
positive) (Figure). The remaining 452 participants (28.4%
[26.2% to 30.6%]) were qSOFA negative.
The Sepsis-3 criteria for sepsis were present in 1,347
participants (84.7% [82.9% to 86.4%]) (sepsis positive).
A total of 1,010 participants (63.5% [61.1% to 65.8%])
were both qSOFA positive and met the Sepsis-3 definition
for sepsis. However, the qSOFA screening tool result was
negative in 337 of the 1,347 participants who were Sepsis-3
sepsis positive (25.0% [22.7% to 27.3%]). Finally, only 203
of the 1,591 ARISE participants (12.8% [11.1% to 14.4%])
fulfilled the Sepsis-3 criteria for septic shock (Figure).Main Results
Of the 1,139 qSOFA-positive participants, 1,099
(96.5% [95.4% to 97.6%]) met the respiratory rate
criterion and 1,022 (89.7% [88.0% to 91.5%]) fulfilled the
blood pressure criterion. Only 379 qSOFA-positive
participants (33.3% [30.5% to 36.0%]) had a GCS score
less than 15 before randomization into the ARISE trial. For
the 452 qSOFA-negative participants, either the respiratory
rate or the blood pressure criteria were present in 241
(53.3% [48.7% to 57.9%]) and 171 (37.8% [33.4% to
42.3%]) participants, respectively. Only 2 participants
(0.4% [0% to 1.1%]) who were qSOFA negative met the
GCS score criterion of less than 15.
The baseline characteristics and outcomes for qSOFA-
positive and -negative participants are shown in Tables 1
and 2, respectively. qSOFA-positive participants had a
higher APACHE II score and received more fluid before
randomization. They were also more likely to meet the
refractory hypotension criteria and receive a vasopressor
infusion. More qSOFA-positive participants received a
vasopressor infusion during their hospital stay, but receipt of
mechanical ventilation and renal replacement therapy was
similar to that of qSOFA-negative participants. Mortality in
qSOFA-positive participants at 90 days was higher, 20.6%Annals of Emergency Medicine 555
Sepsis-3
criteria for sepsis not met
n=115 (25.4%)
90-day mortality 7.8% (n=9)
Sepsis-3 
criteria for sepsis met
n=337 (74.6%)
90-day mortality 16.1% (n=54)
SIRS-based ARISE entry criteria
n=1591 (100%)
90-day mortality 18.7% (n=297)
qSOFA-negative
n=452 (28.4%)
90-day mortality 13.9% (n=63)
qSOFA-positive
n=1139 (71.6%)
90-day mortality 20.5% (n=234)
Sepsis-3
criteria for sepsis not met
n=129 (11.3%)
90-day mortality 10.9% (n=14)
Sepsis-3
criteria for sepsis met
n=1010 (88.7%)
90-day mortality 21.8% (n=220)
Sepsis-3
criteria for septic shock met
n=28 (6.2%)
90-day mortality 32.1% (n=9)
Sepsis-3
criteria for septic shock met
n=175 (15.4%)
90-day mortality 29.1% (n=51)
Figure. Proportion of ARISE participants fulfilling the new Sepsis-3 definitions before randomization into the ARISE trial, and 90-day
mortality.
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17.2%; 63 of 451) for qSOFA-negative participants (risk
difference 6.6%; 95% CI 2.5% to 10.4%).
A respiratory source of infection was more common in
qSOFA-positive participants, with 413 cases (36.3%
[33.5% to 39.1%]) versus 138 (30.6% [26.3% to 34.9%])
among qSOFA-negative participants. A positive blood
culture result was documented in 440 qSOFA-positive
participants (38.6% [35.8% to 41.5%]) and in 161
qSOFA-negative participants (35.6% [31.3% to 40.1%]).
Only 498 of the 1,347 participants (37.0% [34.4% to
39.5%]) who met the Sepsis-3 criteria for sepsis (sepsis
positive) achieved a total SOFA score of greater than or
equal to 2 with only the bedside cardiovascular or central
nervous system components. For the remaining 849 sepsis-
positive participants (63.0% [60.5% to 65.6%]), one or
more SOFA points were derived from laboratory variables
(levels of platelets, bilirubin, creatinine, and PaO2/FiO2)
from blood drawn before randomization (but results were
not necessarily available prerandomization).
For the 337 participants (25% [22.7% to 27.3%]) who
were qSOFA negative but sepsis positive, only 44 (13.1%
[9.5% to 16.7%]) achieved a total SOFA score of greater
than or equal to 2 with just the bedside variables. For the
remaining 293 qSOFA-negative but sepsis-positive
participants (86.9% [83.3% to 90.5%]) in whom556 Annals of Emergency Medicinelaboratory variables contributed to the total SOFA score,
one or more points were derived from the following
variables: creatinine level 35.6%, PaO2/FiO2 level 29.1%,
bilirubin level 23.1%, platelet level 15.1%.
Sepsis-positive participants had a higher APACHE II
score, received more fluid resuscitation and organ support
before randomization (Table 1), and had higher mortality
rates than sepsis-negative participants (Table 2). Ninety-
day mortality for sepsis-positive participants was also more
than double: 20.4% (18.2% to 22.5%; 274 of 1,344
participants) versus 9.4% (5.8% to 13.1%; 23 of 244
participants) for sepsis-negative participants (risk difference
11.0%; 95% CI 6.2% to 14.8%).
The source of infection was not different between the
sepsis-positive and –negative participants: respiratory 466
(34.6% [32.1% to 37.2%]) versus 85 (34.8% [28.9% to
40.8%]), and urinary 257 (19.1% [17.0% to 21.2%])
versus 51 (20.9% [15.8% to 26.0%]), respectively. More
sepsis-positive participants were blood culture positive: 540
participants (40.1% [37.5% to 42.7%]) versus 61 (25.0%
[19.6% to 30.4%]) for sepsis-negative participants.
Of the 203 participants who fulfilled the Sepsis-3
definition for septic shock before randomization, 175
(86.2% [81.5% to 91.0%]) were also qSOFA positive.
Compared with participants who did not fulfill the Sepsis-3
definition for septic shock, those meeting the criteria forVolume 70, no. 4 : October 2017























Age, y 62.9 (16.5) 61.9 (15.9) 63.3 (16.7) 60.1 (17.1) 63.4 (16.3) 63.1 (16.4) 61.5 (16.8)
Sex, No. (%), male 950 (59.7) 279 (61.7) 671 (58.9) 124 (50.8) 826 (61.3) 823 (59.3) 127 (62.6)
APACHE II score 15.6 (6.5) 13.9 (5.9) 16.3 (6.7) 10.5 (4.2) 16.5 (6.5) 15.1 (6.3) 19.3 (6.8)
Refractory hypotension, No. (%) 1,112 (69.9) 183 (40.5) 929 (81.6) 137 (56.1) 975 (72.4) 947 (68.2) 165 (81.3)
Hypoperfusion, No. (%) 736 (46.3) 293 (64.8) 443 (38.9) 125 (51.2) 611 (45.4) 609 (43.9) 127 (62.6)
Interventions before randomization
Invasive ventilation, No. (%) 135 (8.5) 31 (6.9) 104 (9.1) 3 (1.2) 132 (9.8) 85 (6.1) 50 (24.6)
Vasopressor, No. (%) 346 (21.7) 50 (11.1) 296 (26.0) 5 (2.0) 341 (25.3) 143 (10.3) 203 (100)
Total intravenous fluid, mL/kg 34.6 (19.8) 30.3 (19.6) 36.4 (19.6) 32.9 (22.9) 35.0 (19.2) 39.4 (20.6) 34.0 (19.6)
Physiologic and laboratory variables before randomization














Pulse rate, beats/min 105 (22) 106 (23) 104 (21) 103 (19) 105 (23) 105 (22) 106 (25)
Respiratory rate, breaths/min 24.8 (7.8) 23.1 (8.0) 25.5 (7.6) 24.6 (7.5) 24.9 (7.8) 24.8 (7.8) 24.8 (7.6)
Mean arterial pressure, mm Hg 69.9 (15.4) 77.4 (15.8) 67.0 (14.3) 73.2 (14.8) 69.3 (15.5) 70.2 (15.3) 68.4 (16.5)
GCS score 14.3 (1.8) 15 (0.4) 14.0 (2.1) 14.9 (0.2) 14.2 (2.0) 14.4 (1.7) 13.8 (2.5)
SpO2, % 96.6 (4.3) 96.6 (3.7) 96.6 (4.5) 96.9 (3.6) 96.6 (4.4) 96.7 (4.2) 96.0 (5.0)
pH 7.35 (0.12) 7.35 (0.12) 7.35 (0.12) 7.36 (0.10) 7.35 (0.12) 7.36 (0.11) 7.29 (0.15)
Lactate, mmol/L 4.3 (3.1) 4.7 (2.8) 4.1 (3.2) 4.2 (2.4) 4.3 (3.2) 4.1 (2.9) 5.3 (3.8)
Creatinine, median (IQR), mmol/L 131 (93–203) 121 (89–180) 135 (95–210) 85 (69–101) 145 (105–220) 125 (91–188) 204 (126–318)
Urine output, median (IQR), mL/h 50 (0–150) 60 (0–200) 45 (0–145) 100 (20–240) 40 (0–150) 50 (0–160) 30 (0–100)
WBC count109/L, mean (SD) 13.6 (9.7) 13.6 (8.7) 13.7 (10.1) 13.9 (8.2) 13.6 (9.9) 13.6 (9.5) 13.5 (11.1)
Platelet count109/L, mean (SD) 206 (114) 215 (120) 203 (111) 256 (100) 197 (114) 210 (115) 181 (100)
Bilirubin, median (IQR), mmol/L 17 (10–27) 17 (10–29) 17 (10–26) 12 (9–16) 17 (11–30) 16 (10–27) 18 (11–30)
IQR, Interquartile range.
*Data are presented as mean (SD) or number (%) unless otherwise indicated.
Peake et al 2016 Consensus Definitions of Sepsis and Septic Shock and Future Sepsis Researchseptic shock had a higher APACHE II score, received more
organ support before randomization (Table 1), and had
worse outcomes, with higher mortality and greater receipt
and duration of invasive ventilation, vasopressor support,
and renal replacement therapy (Table 2). Ninety-day
mortality was 29.6% (23.3% to 35.8%; 60 of 203) for
participants meeting the Sepsis-3 definition for septic shock
and 17.1% (15.1% to 19.1%; 237 of 1,388) for those who
did not (risk difference 12.5%; 95% CI 6.3% to 19.4%).
There was no difference in the source of infection
between participants meeting the Sepsis-3 definition for
septic shock and those who did not: respiratory 71 (35.1%
[28.6% to 41.7%]) versus 480 (34.6% [32.3% to 37.2%]),
and urinary tract 31 (15.3% [10.4% to 20.3%]) versus 277
(20.0% [17.9% to 22.1%]). Blood culture results were
positive in 98 participants (48.3% [41.4% to 55.2%])
fulfilling the definition for Sepsis-3 septic shock and 503
(36.2% [33.7% to 39.8%]) who did not.
Data for calculation of the qSOFA and SOFA scores and
for determination of septic shock were missing for less than
1% of clinical variables, other than for GCS score, which
was not available for 8.2% of participants (Figure E1,
available online at http://www.annemergmed.com). For
laboratory variables, other than for PaO2/FiO2, which wasVolume 70, no. 4 : October 2017missing for 61.2% of participants, the remainder were
available for 84% to 96% of participants.
Assuming all missing values to be abnormal, the
proportion of patients meeting the qSOFA (71.6%), sepsis
(84.7%), and septic shock (15.2%) criteria increased to
75.5% (73.3% to 77.6%), 99.1% (98.7% to 99.6%), and
28.7% (26.5% to 31.0%), respectively (Table E1, available
online at http://www.annemergmed.com). In accordance
with multiple imputation sensitivity analysis, the median
proportion of patients meeting the qSOFA, sepsis, and
septic criteria was 74.1% (71.9% to 76.3%), 96.3%
(95.3% to 97.2%), and 16.0% (14.1% to 17.8%),
respectively. Sensitivity, specificity, and predictive value of
the Sepsis-3 definitions for 90-day mortality using the
sensitivity analyses to account for missing data are
presented in Table E1, available online at http://www.
annemergmed.com.
LIMITATIONS
First, our study was limited to patients presenting to the
ED with early septic shock who were eligible for
recruitment into the ARISE trial. The number of patients
who may have met the new SOFA-based definitions for
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558 Annals of Emergency MedicineARISE entry criteria is not known and potentially
underestimates the number of patients eligible for future
septic shock trials.4 The assumption that missing data were
within normal limits may also underestimate the potential
number of eligible patients. However, for most variables
85% to 100% of data was available, and missing data
reflect heterogeneity in clinical practice.
Second, the mortality of patients not eligible for ARISE
is also unknown. Patients with imminent death or expected
death from an underlying condition before 90 days were
not included in ARISE. Accordingly, mortality for
participants meeting the new Sepsis-3 definitions is likely to
be higher in comparison because there were no such
exclusion criteria in the Sepsis-3 development cohorts
according to administrative data.
Third, the numbers of patients who would have gone on
to meet the new definitions for sepsis or septic shock
outside of the context of this clinical trial cannot be reliably
determined because subsequent fulfillment of the new
criteria, in particular, the cardiovascular SOFA score and
the definition of septic shock, both of which depend on the
use of vasopressors, would be affected by the study
intervention postrandomization. By 6 hours
postrandomization, approximately 50% of participants
meeting the new criteria for sepsis at baseline met the new
criteria for septic shock.
Fourth, no conclusions can be drawn for patients who
develop sepsis in either the general ward or in the ICU
because ARISE enrolled only patients meeting the study
entry criteria in the ED.
DISCUSSION
We found that most ARISE participants fulfilled the
Sepsis-3 definition for sepsis before randomization.
Accordingly, baseline characteristics and outcomes were
similar. However, only 1 in 8 participants met the new
definition for septic shock in a trial in which patients were
specifically selected because of refractory hypotension
(hemodynamic shock), a blood lactate level greater than or
equal to 4 mmol/L (cryptic shock), or both. In contrast,
more than two thirds of participants enrolled in the ARISE
trial met the 2001 Consensus Conference definition of
septic shock at baseline (systolic blood pressure <90 mm
Hg despite adequate volume resuscitation).3,7 Although the
blood pressure criterion in the Sepsis-3 definition for septic
shock is similar to that applied in the ARISE trial, the
inclusion of an organ injury score and a blood lactate level
greater than or equal to 2 mmol/L in the new definition led
to a substantial reduction in the number of participants
defined as having septic shock (a greater than 80% decrease
in potential participants).Volume 70, no. 4 : October 2017
Peake et al 2016 Consensus Definitions of Sepsis and Septic Shock and Future Sepsis ResearchSample size calculations may be affected by such a
change in definition because 90-day mortality for patients
meeting the Sepsis-3 definition for septic shock was nearly
double that of patients meeting the ARISE refractory
hypotension criteria. Thus, for example, in applying the
Sepsis-3 definition to a future trial evaluating an
intervention with an anticipated 5% absolute risk
reduction, 1,618 patients with septic shock would be
required (with 80% power and a 2-sided a¼.05) compared
with 2,560 patients with the 2001 Consensus Conference
definition of shock based only on blood pressure.3
However, counteracting this potential decrease in sample
size is the substantial decrease in recruitment rate. Of the
1,591 ARISE participants recruited during 5.5 years, 200
per annum met the criteria for refractory hypotension. In
contrast, with the new criteria, only 40 participants per
annum would meet the criteria for septic shock. Finally,
given the substantial differences in mortality for
participants with septic shock between earlier consensus
conference definitions2,3 and the new Sepsis-3 definition,
contextualizing the results of future septic shock trials will
be problematic.
What effect the Sepsis-3 definition for sepsis would have
on sample size and recruitment is less clear because the
majority of ARISE participants also fulfilled the new sepsis
definition, and therefore 90-day mortality was relatively
unchanged (18.7% versus 20.3%, respectively). This
observation suggests that, in comparison with earlier
consensus conference definitions,3 the new Sepsis-3
definition may not identify a different or more
homogeneous cohort of patients.
The inclusion of patients into trials evaluating sepsis
interventions that are time sensitive, such as those assessing
the effect of early hemodynamic resuscitation, may also be
affected by the new definitions. Although the majority of
ARISE participants met the new sepsis definition, less than
40% achieved the SOFA score of greater than or equal to 2
from variables that are readily available at the bedside
(blood pressure, vasopressor levels, and GCS score). Data
for the majority of participants therefore had to rely on
laboratory variables, the results of which may not be
available in the same timely fashion as vital signs. This lack
of diagnostic immediacy would likely lead to inevitable
delays in meeting trial entry criteria and, hence, delivery of
any early intervention under investigation. A reported
advantage of the SOFA score is that it can be performed
retrospectively.1 However, this feature of the new Sepsis-3
definitions has limited research utility for prospective entry
into a randomized clinical trial in which timeliness of
identification is a high priority.10 Delayed identification
may also have important clinical implications for earlyVolume 70, no. 4 : October 2017aggressive resuscitation in patients presenting to the ED
with a life-threatening infection, particularly because the
new definitions require the presence of established organ
dysfunction and thus identify a sicker population of
infected patients who may be less likely to benefit from
early intervention.
Although qSOFA was developed to assist in the early
identification of patients with suspected infection who are
likely to have a poor outcome, particularly in the ED and
other non-ICU settings, 1 in 4 participants meeting the
new Sepsis-3 definition of sepsis were qSOFA negative.
Also, lactate level, which is not included in the qSOFA
score, was higher in qSOFA-negative participants, which
may limit the utility of qSOFA to identify higher-risk
patients in this population. Furthermore, for qSOFA-
positive patients, the GCS score would appear to add very
little to the early identification of potentially infected
patients.
In summary, our post hoc analysis of the ARISE trial
found that the new SOFA-based Sepsis-3 definition for
sepsis identified the majority of ARISE participants
enrolled with the SIRS-based entry criteria. However, most
participants did not meet the new definition of septic
shock. Application of the new definitions to future sepsis
trials may have a number of potential implications, in
particular for sample size, recruitment rate, screening, early
identification, and randomization. Prospective
observational studies to determine the true effect of the new
definitions on key elements of trial conduct are needed.
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Figure E1. Distribution of variables for calculating the qSOFA and SOFA scores and for determination of septic shock with the
Sepsis-3 definition. The blue bars represent the proportion abnormal, orange the proportion normal, and gray the proportion
missing for each variable, with the documented threshold defining abnormality. BPM, Beats/min.
2016 Consensus Definitions of Sepsis and Septic Shock and Future Sepsis Research Peake et alTable E1. Sensitivity, specificity, and predictive value of the Sepsis-3 definitions for 90-day mortality, with sensitivity analyses for missing
data.







Value, % (95% CI)
Negative
Predictive
Value, % (95% CI)
qSOFA Missing¼normal* 1,139/1,588 71.6 (69.3–73.9) 78.8 (74.1–83.5) 30.1 (27.5–32.7) 20.6 (18.2–23.0) 86.0 (82.7–89.3)
qSOFA Multiple imputation† 1,179/1,588 74.1 (71.9–76.3) 80.8 (76.2–85.4) 27.4 (24.9–29.9) 20.4 (18.1–22.7) 86.1 (82.7–89.5)
qSOFA Missing¼abnormal‡ 1,201/1,588 75.5 (73.3–77.6) 81.5 (77–86) 25.9 (23.5–28.3) 20.2 (17.9–22.5) 85.9 (82.4–89.4)
Sepsis Missing¼normal* 1,347/1,588 84.7 (82.9–86.5) 92.3 (89.2–95.4) 17.1 (15–19.2) 20.4 (18.2–22.6) 90.6 (86.9–94.3)
Sepsis Multiple imputation† 1,532/1,588 96.3 (95.3–97.2) 99.3 (98.3–100.3) 4.4 (3.3–5.5) 19.3 (17.3–21.3) 96.6 (91.9–100)
Sepsis Missing¼abnormal‡ 1,577/1,588 99.1 (98.7–99.6) 100 (100–100) 1.1 (0.5–1.7) 18.9 (16.9–20.9) 100 (100–100)
Septic shock Missing¼normal* 203/1,337 15.2 (13.2–17.1) 23 (17.8–28.2) 86.7 (84.6–88.8) 29.6 (23.2–36.0) 82.2 (79.9–84.5)
Septic shock Multiple imputation† 254/1,588 16.0 (14.1–17.8) 22.6 (17.7–27.5) 85.6 (83.6–87.6) 26.5 (21.0–32.0) 82.8 (80.7–84.9)
Septic shock Missing¼abnormal‡ 457/1,588 28.7 (26.5–31.0) 32.3 (26.9–37.7) 72.1 (69.6–74.6) 21.1 (17.3–24.9) 82.2 (79.9–84.5)
*Missing¼normal signifies missing data are assumed a normal value or assigned a score of zero.
†Multiple imputation assumed data missing at random. A total of 11 imputed data sets were created and median results are reported.
‡Missing¼abnormal signifies missing data are assumed the worst value or assigned a maximum score.
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